Evidence map›Paper›PMID 24968121›Full record

SynthesisPloS one2014

Prognostic value of PLR in various cancers: a meta-analysis.

Xin Zhou, Yiping Du, Zebo Huang, Jun Xu, Tianzhu Qiu, Jian Wang, Tongshan Wang, Wei Zhu, Ping Liu

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 199 papers, 23 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
199citing papers in PubMed, 23 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

199 citing papers in PubMed, 23 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2017
    Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

139 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xin ZhouDepartment of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yiping DuDepartment of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Zebo HuangDepartment of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jun XuDepartment of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Tianzhu QiuDepartment of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jian WangDepartment of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Tongshan WangDepartment of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Wei ZhuDepartment of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Ping LiuDepartment of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRecently, more and more studies investigated the association of inflammation parameters such as the Platelet Lymphocyte Ratio (PLR) and the prognosis of various cancers. However, the prognostic role of PLR in cancer remains controversial.

methodsWe conducted a meta-analysis of published studies to evaluate the prognostic value of PLR in various cancers. In order to investigate the association between PLR and overall survival (OS), the hazard ratio (HR) and its 95% confidence interval (CI) were calculated.

resultsA total of 13,964 patients from 26 studies were included in the analysis. The summary results showed that elevated PLR was a negative predictor for OS with HR of 1.60 (95%CI: 1.35-1.90; Pheterogeneity <0.001). Subgroup analysis revealed that increased PLR was a negative prognostic marker in patients with gastric cancer (HR = 1.35, 95%CI: 0.80-2.25, Pheterogeneity = 0.011), colorectal cancer (HR = 1.65, 95%CI: 1.33-2.05, Pheterogeneity = 0.995), hepatocellular carcinoma (HR = 3.07, 95% CI: 2.04-4.62, Pheterogeneity = 0.133), ovarian cancer (HR = 1.57, 95%CI: 1.07-2.31, Pheterogeneity = 0.641) and non-small cell lung cancer (NSCLC) (HR = 1.85, 95% CI: 1.42-2.41, Pheterogeneity = 0.451) except for pancreatic cancer (HR = 1.00, 95%CI: 0.92-1.09, Pheterogeneity = 0.388).

conclusionThe meta-analysis demonstrated that PLR could act as a significant biomarker in the prognosis of various cancers.

Indexed as

Lymphocyte CountPlatelet CountHumansNeoplasmsOdds RatioPrognosisProportional Hazards Models

Identifiers

PMID24968121
PMCPMC4072728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.